A detailed history of Newbridge Financial Services Group, Inc. transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Newbridge Financial Services Group, Inc. holds 300 shares of EDIT stock, worth $873. This represents 0.0% of its overall portfolio holdings.

Number of Shares
300
Previous 500 40.0%
Holding current value
$873
Previous $3,000 66.67%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Sep 11, 2024

SELL
$4.67 - $7.28 $934 - $1,456
-200 Reduced 40.0%
300 $1,000
Q1 2024

Apr 24, 2024

BUY
$7.03 - $11.07 $1,406 - $2,214
200 Added 66.67%
500 $3,000
Q4 2023

Mar 28, 2024

SELL
$6.25 - $11.11 $18,750 - $33,330
-3,000 Reduced 90.91%
300 $3,000
Q3 2023

Oct 17, 2023

SELL
$6.92 - $9.31 $5,681 - $7,643
-821 Reduced 19.92%
3,300 $25,000
Q1 2023

Apr 18, 2023

SELL
$7.03 - $11.53 $10,481 - $17,191
-1,491 Reduced 26.57%
4,121 $29,000
Q4 2022

Jan 17, 2023

SELL
$8.32 - $13.21 $1,414 - $2,245
-170 Reduced 2.94%
5,612 $0
Q3 2022

Oct 13, 2022

BUY
$12.16 - $19.42 $66,515 - $106,227
5,470 Added 1753.21%
5,782 $71,000
Q2 2022

Jul 15, 2022

SELL
$9.99 - $21.35 $229 - $491
-23 Reduced 6.87%
312 $4,000
Q1 2022

Apr 26, 2022

SELL
$14.08 - $27.63 $2,604 - $5,111
-185 Reduced 35.58%
335 $6,000
Q4 2021

Jan 19, 2022

BUY
$26.55 - $40.57 $4,248 - $6,491
160 Added 44.44%
520 $14,000
Q3 2021

Oct 27, 2021

SELL
$39.27 - $72.94 $95,229 - $176,879
-2,425 Reduced 87.07%
360 $15,000
Q2 2021

Sep 07, 2021

BUY
$31.29 - $56.64 $62,799 - $113,676
2,007 Added 257.97%
2,785 $158,000
Q1 2021

Sep 07, 2021

SELL
$39.71 - $90.58 $7,346 - $16,757
-185 Reduced 19.21%
778 $33,000
Q4 2020

Sep 07, 2021

BUY
$27.07 - $84.35 $8,851 - $27,582
327 Added 51.42%
963 $68,000
Q3 2020

Sep 07, 2021

BUY
$28.06 - $37.16 $17,846 - $23,633
636 New
636 $18,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $200M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Newbridge Financial Services Group, Inc. Portfolio

Follow Newbridge Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Newbridge Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Newbridge Financial Services Group, Inc. with notifications on news.